Micro Labs Expands African Presence With Swipha Acquisition

Micro Labs Limited, India, has acquired Swiss Pharma Nigeria Limited (Swipha), strengthening its presence in Nigeria and creating a stronger platform for expansion across the African pharmaceutical market. The acquisition brings together Micro Labs' pharmaceutical capabilities with Swipha's local manufacturing, distribution and market experience. Micro Labs has confirmed that the existing Swipha employees will be retained.

Swipha, which was established in 1976, manufactures, markets and distributes branded generic medicines and has a portfolio covering areas such as anti-malarials, anti-infectives, cardiovascular medicines, anti-diabetic treatments and central nervous system therapies. The company has also achieved WHO prequalification for zinc dispersible tablets and sulfadoxine-pyrimethamine.

🌍 Why the Acquisition Matters

★ Stronger Nigerian Presence — Expands Micro Labs' existing operations in the Nigerian pharmaceutical market.

★ African Expansion — Provides a platform to reach neighbouring African markets.

★ Local Manufacturing — Swipha's WHO-approved manufacturing facility can support production and exports.

★ Broader Medicine Portfolio — Combines the companies' therapeutic portfolios to provide more treatment options.

★ Supply Chain Strength — Swipha's established distribution network and CRM capabilities can improve market reach and supply-chain efficiency.

💊 Areas of Potential Impact

◆ Anti-Malarial Medicines

◆ Anti-Infective Treatments

◆ Cardiovascular Medicines

◆ Diabetes and Metabolic Care

◆ Central Nervous System Therapies

🔬 Combining Pharmaceutical Capabilities

Micro Labs operates across the pharmaceutical value chain, including research and development, active pharmaceutical ingredients and finished formulations. The company also has a network of 14 formulation plants, including injectable and bulk-drug facilities.

The acquisition is expected to create synergies between Micro Labs' broader pharmaceutical capabilities and Swipha's local infrastructure. According to Micro Labs, combining the two businesses can help improve efficiency, broaden treatment choices and support the manufacture and export of products to neighbouring countries.

The transaction therefore represents more than an expansion of commercial operations. It gives Micro Labs a stronger local manufacturing and distribution platform in Nigeria while supporting its longer-term objective of expanding access to affordable medicines across African markets.